Astragaloside IV alleviates placental oxidative stress and inflammation in GDM mouse

in Endocrine Connections
View More View Less
  • 1 L Zhou, Cangzhou Central Hospital, Cangzhou , China
  • 2 R Zhang, Cangzhou Central Hospital, Cangzhou, 061000, China
  • 3 S Yang, Cangzhou Central Hospital, Cangzhou, China
  • 4 Y Zhang, Cangzhou Central Hospital, Cangzhou, China
  • 5 D Shi, Cangzhou Central Hospital, Cangzhou, China

Correspondence: Ruixue Zhang, Email:

Background: Our previous study revealed that astragaloside IV (AS-IV) effectively improved gestational diabetes mellitus (GDM) by reducing hepatic gluconeogenesis. Due to the importance of placental oxidative stress, we further explored the protective role of AS-IV on placental oxidative stress in GDM.

Methods: First, non-pregnant mice were orally administrated with AS-IV to evaluate its safety and effect. Then GDM mice were orally administered with AS-IV for 20 days and its effect on the symptoms of GDM, placental oxidative stress, secretions of inflammatory cytokines, as well as toll-like receptor 4 (TLR4)/NF-κB signaling pathway, were evaluated.

Results: AS-IV had no adverse effect on non-pregnant mice. On the other hand, AS-IV significantly attenuated the GDM-induced hyperglycemia, glucose intolerance, insulin resistance, placental oxidative stress, productions of inflammatory cytokines and the activation of TLR4/NF-κB pathway.

Conclusion: AS-IV effectively protected against GDM by alleviating placental oxidative stress and inflammation, in which TLR4/NF-κB might be involved.

If the inline PDF is not rendering correctly, you can download the PDF file here.


     European Society of Endocrinology

     Society for Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 167 167 167
PDF Downloads 36 36 36